🇺🇸 Intranasal ketamine in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Agitation — 1 report (10%)
- Angioedema — 1 report (10%)
- Application Site Pain — 1 report (10%)
- Delusion — 1 report (10%)
- Depression — 1 report (10%)
- Disinhibition — 1 report (10%)
- Dissociation — 1 report (10%)
- Drug Ineffective — 1 report (10%)
- Hallucination, Visual — 1 report (10%)
- Hypertension — 1 report (10%)
Other Psychiatry / Pain Management approved in United States
Frequently asked questions
Is Intranasal ketamine approved in United States?
Intranasal ketamine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Intranasal ketamine in United States?
Rhode Island Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.